Hochul Escalates Kalshi Fight Over FDA Drug-Approval Markets With Social Media Broadside

New York Governor Kathy Hochul has taken the state's $36 billion lawsuit against Kalshi to social media, accusing the prediction market operator of "turning cancer patients into prop bets" over its FDA drug-approval contracts. Kalshi's co-founder fired back within hours, and Harvard Medical School researchers have separately asked the CFTC to ban the markets entirely.

• New York Governor Kathy Hochul posted on X on 5 August 2026 accusing Kalshi of "turning cancer patients into prop bets" over its markets on FDA drug-approval outcomes
• Kalshi co-founder and COO Luana Lopes Lara responded the following day, calling Hochul's characterisation "a flat out lie" and arguing the contracts bring transparency and efficiency to drug development
• New York filed suit against Kalshi in state court on 31 July 2026, seeking $36 billion, calculated as three times Kalshi's gains plus $100,000 per bet placed in the state
• Researchers at Harvard Medical School and Brigham and Women's Hospital have separately filed a public comment with the CFTC urging it to prohibit drug-trial prediction markets, warning of incentives for insider trading on confidential clinical data
• The social media exchange follows a series of failed Kalshi bids to move state enforcement actions to federal court, with New York the largest state yet to pursue a full ban on the company's contracts
• The New York Times has reported Kalshi is planning to extend its offering to contracts on drugs still in clinical trials, widening the scope of the controversy

The Dispute Over Kalshi's FDA Markets Has Moved From the Courtroom to the Public Arena

New York Governor Kathy Hochul escalated the state's legal confrontation with Kalshi on 5 August 2026, posting on X that the prediction market operator was "turning cancer patients into prop bets". The post referenced Kalshi's practice of offering event contracts on whether the Food and Drug Administration will approve drugs across a range of conditions, including various cancers. According to reporting by the New York Times, Kalshi is also preparing to list contracts on drugs that remain in the trial stage, a move that broadens the category significantly.

Kalshi co-founder and chief operating officer Luana Lopes Lara responded on 6 August, describing Hochul's framing as "a flat out lie" and arguing that the contracts are focused on FDA approval outcomes, not patient conditions, and that such markets "can bring more transparency and efficiency to a complex industry". The exchange drew a wide range of reactions, including a contribution from Renny Zucker of Citrini Research, who noted a structural distinction between capital markets and prediction markets: equity markets channel capital into the economy, whereas prediction markets do not.

The social media exchange comes less than a week after New York filed suit against Kalshi in state court on 31 July 2026, seeking $36 billion in penalties. The state arrived at that figure by applying a multiplier of three to Kalshi's total gains and adding $100,000 for every bet placed within New York. Kalshi has reportedly brought in $1.6 billion in fees since its launch, and its most recent fundraising round valued the company at $22 billion. The state's complaint characterises Kalshi's operation as "quintessentially gambling" and alleges the company has been running without a New York gaming licence. Kalshi has already attempted to transfer the case to federal court, a tactic it has deployed in multiple other state enforcement actions and lost each time, according to court records.

If New York prevails, it would become the largest state to prohibit Kalshi's contracts. Kalshi has previously faced enforcement in Nevada, Michigan, Washington and other jurisdictions, with courts consistently declining to grant the company injunctions against state-level action. A federal judge also denied Kalshi's bid to block New York's enforcement earlier in the litigation, and the Second Circuit upheld that outcome before the state filed its suit at 12:01 a.m. on 31 July, the first minute it was permitted to do so.

The Harvard Letter Adds a Separate and More Specific Warning

Separately from the New York litigation, researchers at Harvard Medical School and Brigham and Women's Hospital filed a public comment with the Commodity Futures Trading Commission last month, calling on the regulator to prohibit prediction markets built around drug trials. The letter was authored by Dr Thomas Hwang and the hospital's Program on Regulation, Therapeutics, and Law. Its central concern is that the small circle of individuals who have access to live trial data, including independent safety board members, site investigators, and patients themselves, would face direct financial incentives to trade on confidential health information if a liquid market exists. The researchers raised specific concerns that patients could misreport symptoms to protect a market position, or that an investigator could attempt to influence recorded results. The CFTC has separately opened a formal rulemaking process for prediction markets and is under increasing congressional pressure over how it supervises the sector.

The FDA-Approval Markets Are a Different Regulatory Problem From Sports Contracts

Most of the legal friction between Kalshi and US state regulators has centred on sports event contracts, with states arguing those products constitute unlicensed gambling and Congress split on how to classify the sector. The FDA drug-approval contracts introduce a distinct problem: they are not primarily a gambling-classification question but an insider-trading and clinical-integrity question. The Harvard researchers' concern is structural rather than political. A market that prices the probability of a binary regulatory outcome, when a defined group of people holds non-public information that resolves that outcome, creates incentives that securities and clinical-trial law were designed to prevent. Whether the CFTC's existing framework under the Commodity Exchange Act is adequate to address that risk, or whether it requires additional action, is a question the regulator has not yet answered publicly.

Hochul's Social Media Post Is Strategically Timed, Not Merely Rhetorical

Governor Hochul's choice to take the argument to X rather than leave it to court filings reflects a calculated public-opinion strategy. By framing FDA markets in terms of cancer patients rather than jurisdictional disputes, the state positions itself in a register that is accessible to a broad audience and difficult for Kalshi to rebut without appearing to validate the most emotive version of the criticism. Lopes Lara's response was direct but necessarily technical, and technical arguments rarely win in the court of public opinion. The timing, days after a federal judge declined to block the state's enforcement and as the $36 billion suit moved forward, suggests New York intends to keep the reputational and legal pressure running in parallel. Kalshi's characterisation of the markets as tools for researchers and investors may be accurate in part, but it does not address the insider-trading concern the Harvard letter raises, and that gap will remain available to critics for as long as the CFTC has not resolved the question formally.

The CFTC Is Now the Decisive Arena, and the Outcome Is Unresolved

Every thread in this dispute, the state litigation, the Harvard comment letter, the congressional hearings, and the social media exchange, runs back to the same unanswered question: what the CFTC will ultimately decide about the permissible scope of event contracts. Kalshi has sought CFTC approval for a broad range of sports and event markets, arguing that federal designation pre-empts state gambling law. The US House subcommittee hearing on prediction markets has added political weight to that process without resolving it. Until the CFTC acts, state enforcement and federal pre-emption arguments will continue to collide in court, and the FDA drug-approval question will remain the sharpest edge of the debate: a category where the harm argument is specific, the affected parties are identifiable, and the political optics are unfavourable to the operator. New York has positioned itself to win the public argument even if the legal outcome remains uncertain for months.